Integrated Investment Consultants’s Vertex Pharmaceuticals VRTX Stock Holding History

Integrated Investment Consultants’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-19,734	Closed	-$42K	–	381
2024 Q3	$42K	Buy	+19,734	New	+$9.48M	0.01%	315
2018 Q2	–	Sell	-151	Closed	-$25K	–	686
2018 Q1	$25K	Buy	+151	New	+$24.7K	0.01%	518
2017 Q3	$23K	Buy	151 +28	+23%	+$4.21K	0.01%	451
2017 Q2	$16K	Hold	123	–	–	0.01%	485
2017 Q1	$13K	Hold	123	–	–	0.01%	496
2016 Q4	$9K	Buy	123 +26	+27%	+$2.12K	﹤0.01%	514
2016 Q3	$8K	Hold	97	–	–	﹤0.01%	525
2016 Q2	$8K	Hold	97	–	–	﹤0.01%	537
2016 Q1	$8K	Buy	+97	New	+$8.77K	﹤0.01%	522

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Integrated Investment Consultants's VRTX Position: Q4 2024 in Review

Integrated Investment Consultants sold out of Vertex Pharmaceuticals (VRTX) in Q4 2024, closing a stake of 19,734 shares — an estimated $42K sold.

Integrated Investment Consultants first reported a position in VRTX in Q1 2016 and held it in 9 quarters. The position peaked at $42K in Q3 2024. 1,564 funds tracked by Wall St. Rank hold VRTX as of Q4 2024.

Integrated Investment Consultants reported no remaining Vertex Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Integrated Investment Consultants sold 19,734 Vertex Pharmaceuticals shares in Q4 2024, an estimated $42K.
Integrated Investment Consultants first reported a position in Vertex Pharmaceuticals in Q1 2016 and held it in 9 quarters.
Integrated Investment Consultants's Vertex Pharmaceuticals position peaked at $42K in Q3 2024.
1,564 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2024.

Based on Integrated Investment Consultants's 13F filing for Q4 2024, filed 15 Jan 2025.